# Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

> **NCT04729595** · PHASE2,PHASE3 · TERMINATED · sponsor: **Adamis Pharmaceuticals Corporation** · enrollment: 248 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Tempol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04729595
- **Lead sponsor:** Adamis Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-09-21
- **Final completion:** 2022-09-21
- **Target enrollment:** 248 (ACTUAL)
- **Why stopped:** Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo
- **Last updated:** 2022-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729595, "Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04729595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*